January Reflections: Why 2026 Must Be the Year We Accelerate Cervical Cancer Elimination

January 14, 2026

Every January, as Cervical Cancer Awareness Month begins, we find ourselves returning to the same glaring contradiction: cervical cancer is almost entirely preventable, yet it still claims more than 340,000 lives every year, most of them in low-resource settings where women have the least access to care. It’s a disease for which we have extraordinary tools. The challenge is not scientific discovery anymore; it’s the real-world work of scaling the tools that we already know save lives.

As we step into 2026, the global conversation around cervical cancer feels more urgent, more coordinated, and more optimistic. Yes, the disparities remain unacceptable. But the momentum is real. This month offers a moment to examine where progress is happening, where implementation is falling short, and how vaccination, high-performance screening, and implementation science can bring us closer to the promise of elimination.

A Vision Within Reach

If you’ve followed the WHO Cervical Cancer Elimination Initiative, you know that its 90–70–90 targets have become a guiding benchmark for public health:

90% of girls vaccinated with HPV vaccine by age 15
70% of women screened by ages 35 and 45
90% of women with pre-cancer or invasive cancer receiving appropriate treatment

These numbers are more than metrics; they represent a bold but achievable vision of a world where cervical cancer becomes rare. In some places, early progress is already visible. Rwanda and Bhutan continue to achieve remarkably high HPV vaccination coverage. Australia remains on track to eliminate cervical cancer within the next decade. Several countries in Latin America and the Western Pacific have executed bold national screening transitions.

Despite more than 130 countries introducing large-scale HPV vaccination, the gap between early adopters and under-resourced health systems is still wide. That gap is where implementation science, and innovation grounded in community realities, must take center stage.

HPV Vaccination: Moving Beyond “Does It Work?” to “Does It Work Everywhere?”

One theme that comes up repeatedly is this: the science behind the HPV vaccine is well established. The challenge is making delivery equitable, consistent, and resilient.

In countries that have succeeded, a few patterns stand out. School-based delivery remains one of the strongest determinants of high coverage, especially when combined with trusted messengers like teachers, nurses, and local leaders. Where schools can’t reach everyone, flexible community strategies matter. We’re also seeing the impact of the single-dose vaccine recommendation, which lowers costs and barriers for countries trying to introduce or reintroduce HPV vaccination after pandemic disruptions.

Programs still face real-world obstacles:

Vaccine supply limitations
Misinformation and hesitancy
Difficulties reaching out-of-school adolescents
Workforce shortages

Implementation studies from low and middle-income countries (LMICs) make this clear: trust and access shape vaccination uptake. Some of the most impactful strategies have been simple: peer support groups, local champions, or tools that give parents clear, culturally relevant information about the vaccine. These community-driven approaches are not “nice to have”; they are essential for scale-up.

And when vaccination scales, the impact becomes visible. Real-world evidence now shows declines in HPV infections, high-grade lesions, and even early cervical cancer incidence in vaccinated cohorts. Every year, that evidence gets stronger.

Screening: The Shift Toward HPV Testing and What It Means for Access

Vaccination protects the next generation, but screening saves lives today. One of the most encouraging global trends is the growing shift from Pap tests to HPV testing, which is more sensitive and more adaptable to a range of health settings.

This transition is especially important for LMICs, because HPV testing:

Works with longer screening intervals
Can be paired with self-sampling, expanding reach
Reduces dependence on cytology infrastructure

Self-sampling, in particular, is gaining traction. Women consistently report feeling more comfortable and more in control when they can collect samples themselves. For health systems with limited workforce or long travel distances, self-sampling is not simply a convenience, it’s a pathway to equity.

But effective screening is much more than the test itself. Success depends on the full sequence: referral, treatment, and follow-up. Programs in Malawi, Zambia, and parts of Latin America continue to show that integrated models, such as combining screening with HIV services or community outreach, can dramatically increase uptake and reduce loss to follow-up.

These examples remind us that technology alone will never be enough. The implementation pathway determines whether women actually complete the journey from screening to treatment.

Implementation Science: Where the Real Work Happens

If you ask public health teams what they need most right now, many won’t say “new tools.” They’ll say: “How do we make these tools work in our community?”

That is the promise of implementation science. It examines not only the effectiveness of interventions, but their feasibility, acceptability, sustainability, and equity. It is the bridge between translational research and lived experience.

Across LMICs, implementation science is shaping cervical cancer programs in important ways:

Using human-centered design to adapt services to local norms
Testing differentiated delivery models, from mobile clinics to weekend hours
Studying costs and operational workflows to support national scale-up
Integrating screening with existing touchpoints such as maternal health or HIV programs

These approaches are not theoretical. They are being used right now to reach women who would otherwise remain unseen by the health system.

And this is where the field is headed: toward solutions that are practical, adaptable, and deeply informed by local context.

Where We Go From Here

So what should we carry into 2026?

First, a sense of urgency. Cervical cancer is preventable, but only if prevention reaches the women and girls who need it most.

Second, a sense of possibility. We have more evidence, more tools, and more momentum than ever before.

And finally, a commitment to equity, not as an aspiration, but as a measurable outcome that guides decision-making.

The coming year will demand stronger partnerships, better data systems, faster adoption of HPV testing, and renewed focus on reaching underserved communities. It will also require investment in the people doing the work on the ground: nurses, midwives, community health workers, and local leaders who are often the backbone of cervical cancer programs.

Cervical cancer elimination is not just a scientific milestone. It is a moral imperative. And it is within reach if we choose to act decisively.